Open an account

Aardvark Therapeutics

AARD · NASDAQ

$3.90+$0.16 (+4.28%)TodayMarket closed ·
Prev close $3.74

About AARD

Aardvark Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in San Diego, California and currently employs 40 full-time employees. The company went IPO on 2025-02-13. The firm targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. The company is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Employees
40
Headquarters
San Diego, California
Listed
Feb 13, 2025
Sector
Health Care
Industry
Pharmaceuticals
Website
aardvarktherapeutics.com

AARD key statistics

Market cap
85.35M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
121.29K
Volume
66.71K
Open price
$3.80
High today
$4.05
Low today
$3.78
52 Week high
$16.60
52 Week low
$3.35

Aardvark Therapeutics (AARD) at a glance

As of Oct 20, 2026, Aardvark Therapeutics (AARD) shares are priced at $3.90, giving the company a market cap of 85.35M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.78 and $4.05. The current price is 3.2% above the day's low and 3.7% below its high.

Volume so far is 66.71K shares, below the average of 121.29K shares a day.

Over the past year Aardvark Therapeutics has ranged from $3.35 to $16.60, and now sits 4% of the way up that range.

Aardvark Therapeutics met or beat analyst EPS estimates in 3 of the last 6 quarters. In Q2 FY26 it reported -$0.66 per share against an estimate of -$0.8917.

The average analyst price target is $14.28, 266.2% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

38%of 8 analyst ratings say Buy
  • Buy37.5%
  • Hold50.0%
  • Sell12.5%
Price target · 13 analystsAvg $14.28
Low
$3.03
Now
$3.90
High
$47.25

AARD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 6 quarters, by 12.8% on average.

  1. Q1 FY25: reported -$0.71 per share against an estimate of -$0.6868
  2. Q2 FY25: reported -$0.66 per share against an estimate of -$0.612
  3. Q3 FY25: reported -$0.75 per share against an estimate of -$0.8145
  4. Q4 FY25: reported -$0.81 per share against an estimate of -$0.8494
  5. Q1 FY26: reported -$0.99 per share against an estimate of -$0.8948
  6. Q2 FY26: reported -$0.66 per share against an estimate of -$0.8917

AARD news

  • Press releaseGlobe Newswire

    Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD

  • Press releaseBusiness Wire

    CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

  • Press releasePRNewswire

    AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit

  • Press releasePRNewswire

    AARD FINAL DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

  • Press releasePRNewswire

    Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD

  • Press releaseGlobe Newswire

    URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th

  • Press releasePRNewswire

    Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit

  • Press releasePRNewswire

    AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities Lawsuit - Contact SueWallSt

Similar companies

Companies in the same industry as Aardvark Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.